Rethinking Oncology Development: Master Protocols May Shorten Time To Approval
This article was originally published in RPM Report
Executive Summary
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”